Discuss the scientific challenges in developing an effective dengue vaccine. In this context, evaluate the significance of India's approval of the Qdenga vaccine.

Dengue is caused by four antigenically distinct serotypes (DENV-1 to DENV-4), which makes a single vaccine far harder to design than for a single-pathogen disease. India's recent approval of Qdenga, its first dengue vaccine, is therefore a genuine scientific milestone — but one whose public health value depends on how it is priced and targeted.

Scientific challenges in dengue vaccine development

• Four-serotype problem: a vaccine must generate balanced, durable immunity against all four serotypes at once; partial immunity can be worse than none.
• Antibody-dependent enhancement (ADE): a second infection with a different serotype can worsen disease, so weak or unbalanced vaccine-induced antibodies risk aggravating illness.
• Safety in dengue-naïve recipients: the earlier Dengvaxia experience in the Philippines (2017) forced global regulators to insist on evidence of safety in those never previously infected.
• Uneven serotype efficacy: live-attenuated tetravalent candidates rely on a single backbone, giving stronger protection against some serotypes than others.
• Trial complexity: efficacy must be shown across varied endemic settings and long follow-up; Qdenga required multi-country trials, including a Phase III study in the Indian population [1][2].

Evaluating the significance of Qdenga's approval

• Merits: CDSCO granted marketing authorisation to the live-attenuated tetravalent vaccine built on a DENV-2 backbone using recombinant DNA technology [1][3]; it needs no pre-vaccination screening, is WHO-prequalified with high efficacy against virologically confirmed dengue [2], and complements vector control under the National Vector Borne Disease Control Programme [1].
• Limits: approval is a regulatory step, not a pricing or procurement decision; WHO recommends its use mainly in high-transmission settings and specific age groups [2]; protection against some serotypes remains less certain, and rising DENV-3 circulation in India could blunt real-world impact.

Qdenga's approval strengthens India's dengue toolkit without replacing surveillance and vector control. Its promise will be realised only if pricing and public procurement make it reach the highest-risk populations, alongside the indigenous DengiAll candidate now in Phase 3 trials [4] — advancing both health equity and SDG-3.